NCAM1 and leukemia: However, we noted that CD16-CD56bright as well as CD16+CD56+ cells showed increased expression of DNAM-1 after the first cycle of HDC/IL-2 (Figure 2C), and patients with above median increase in fluorescence intensity (MFI) values between treatment start and three weeks of treatment showed superior leukemia-free survival as compared with patients with low or no increase in DNAM-1 expression (Figures 2D, E and Supplemental Table 1; log rank test, p=0.03 and p=0.1 for LFS and OS, respectively).